Francisco Partners Iv, L.P. Sells 447,259 Shares of GoodRx (NASDAQ:GDRX) Stock

GoodRx Holdings, Inc. (NASDAQ:GDRX) major shareholder Francisco Partners Iv, L.P. sold 447,259 shares of the company’s stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $3.52, for a total value of $1,574,351.68. Following the completion of the sale, the insider owned 913,592 shares in the company, valued at $3,215,843.84. This represents a 32.87% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Francisco Partners Iv, L.P. also recently made the following trade(s):

• On Friday, August 21st, Francisco Partners Iv, L.P. sold 274,717 shares of GoodRx stock. The stock was sold at an average price of $3.50, for a total value of $961,509.50.
• On Wednesday, August 19th, Francisco Partners Iv, L.P. sold 471,975 shares of GoodRx stock. The stock was sold at an average price of $3.53, for a total value of $1,666,071.75.

GoodRx Stock Down 3.1%

GDRX stock opened at $3.45 on Friday. The company has a current ratio of 1.38, a quick ratio of 1.38 and a debt-to-equity ratio of 0.74. The firm has a market capitalization of $1.18 billion, a PE ratio of 86.27, a PEG ratio of 1.72 and a beta of 1.60. GoodRx Holdings, Inc. has a 1-year low of $1.77 and a 1-year high of $5.81. The business’s 50 day simple moving average is $3.13 and its 200 day simple moving average is $2.63.

GoodRx (NASDAQ:GDRX) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $0.08 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.08. GoodRx had a return on equity of 7.22% and a net margin of 2.07%.The business had revenue of $200.41 million for the quarter, compared to analysts’ expectations of $193.23 million. During the same quarter in the prior year, the business earned $0.09 EPS. The firm’s revenue for the quarter was down 1.3% on a year-over-year basis. As a group, research analysts anticipate that GoodRx Holdings, Inc. will post 0.16 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GDRX. Lazard Asset Management LLC increased its position in GoodRx by 43.6% during the 2nd quarter. Lazard Asset Management LLC now owns 17,142 shares of the company’s stock worth $85,000 after buying an additional 5,201 shares during the period. Brevan Howard Capital Management LP lifted its holdings in shares of GoodRx by 7.7% during the third quarter. Brevan Howard Capital Management LP now owns 95,483 shares of the company’s stock worth $404,000 after buying an additional 6,842 shares in the last quarter. Hirtle Callaghan & Co LLC boosted its position in shares of GoodRx by 60.3% in the fourth quarter. Hirtle Callaghan & Co LLC now owns 18,261 shares of the company’s stock valued at $49,000 after acquiring an additional 6,869 shares during the period. Tower Research Capital LLC TRC boosted its position in shares of GoodRx by 202.3% in the second quarter. Tower Research Capital LLC TRC now owns 11,327 shares of the company’s stock valued at $56,000 after acquiring an additional 7,580 shares during the period. Finally, Quarry LP bought a new stake in shares of GoodRx in the third quarter valued at about $33,000. 63.77% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have recently weighed in on GDRX. TD Cowen increased their price objective on shares of GoodRx from $4.00 to $5.00 and gave the company a “buy” rating in a research report on Tuesday, August 11th. Citigroup lifted their target price on shares of GoodRx from $4.00 to $5.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Wells Fargo & Company upped their price target on shares of GoodRx from $3.50 to $5.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Wall Street Zen raised shares of GoodRx from a “hold” rating to a “buy” rating in a report on Saturday, August 15th. Finally, Barclays raised their price objective on shares of GoodRx from $3.00 to $4.00 and gave the stock an “underweight” rating in a research report on Thursday. Four analysts have rated the stock with a Buy rating, six have given a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $4.23.

About GoodRx

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.